Bionomics initiates Phase II clinical study of BNC210 for the treatment of anxiety and depression
22 April 2015 | By Victoria White
Bionomics has initiated a Phase II clinical study of BNC210, the Company’s drug candidate in development for the treatment of anxiety and depression...